Synthetic Biology Market Size & Share 2026-2035

Synthetic Biology Market Size

The global synthetic biology market was valued at USD 25.6 billion in 2025. The market is expected to grow from USD 30.1 billion in 2026 to USD 128.1 billion in 2035, at a CAGR of 17.5% according to latest report published by Global Market Insights Inc.

• Synthetic biology is a field that plays a transformative role by coupling engineering principles with biological systems so that novel biological components, devices, and systems can be designed and constructed. These contemporary practices of synthetic biology have undergone an evolutionary transition from more basic genetic engineering manipulations to the development of advanced platforms that allow programmed manipulation of cellular functions with an unprecedented level of accuracy.
• This change has been fueled by exponential advances in DNA synthesis and sequencing technologies, computational biology tools, and an ever-increasing understanding of biological design principles. The marketplace covers enabling products that include oligonucleotides, enzymes, and chassis organisms; core products such as synthetic genes, cells, and DNA libraries; as well as enabled products including pharmaceuticals, industrial chemicals, biofuels, and biomaterials.

 Synthetic Biology Market Trends

• Changing interest in CRISPR and genome editing technologies: The application of CRISPR-Cas9 and other next-generation genome-editing technologies has created waves toward the adoption of synthetic biology in all spectra of use-from therapeutic applications to agro-industrial ones. The most transverse event in the field was the FDA clearance in 2023 as the first CRISPR-based therapy for sickle-cell disease. Clinical trials showed marvellous efficacy rates with 83% of patients suffering from B-cell acute lymphoblastic leukaemia who received CRISPR-engineered CAR-T cells achieving remission.  

• Bringing AI within the domain of bioinformatics tools: This merging of artificial intelligence with synthetic biology is essentially changing the research and development workflow regarding designing biological systems with computer precision. Machine learning has shown to have the capacity to optimize protein yields, whereby ML-enabled strain development achieved 1.8 times improvements over standard methods. The release of AlphaFold 3 in 2024 extended predictive capability to include protein-DNA, protein-RNA, and protein-ligand interactions in addition to protein structures, thereby opening up a new level of understanding for the development of synthetic biological systems.

• The rise of sustainable and eco-friendly bioproducts in demand: The environment altogether tension for synthetic biology to serve as an alternative to petroleum products and current resource consumption. Analyses show that 60% of tangible inputs into the global economy can potentially be biologically produced, which signifies a huge step transformation in synthetic biology. Chemicals and materials manufactured biomanufacturing are relatively high-on environmental benefits, where life cycle assessments show up to 96% reduction in greenhouse gas emissions for cellular agriculture products compared with conventional beef production.

Synthetic Biology Market Analysis

Based on product type, the synthetic biology market is segmented into core products, enabling products and enabled products. Enabled products dominated the market with an approximate market share of 67.5% in 2025 and is expected to grow with a CAGR of 17.4% by 2035.

• Enabled products consist of synthetic biology outputs which various industries use for commercial production these outputs include bio-based chemicals, advanced materials, engineered therapeutics, industrial enzymes, sustainable fuels, and agricultural biologicals. The market segment generates the highest revenue because it enables companies to directly sell their products while delivering value to various industries through these goods.
• Enabling products consists of tools and technologies and reagents that scientists use throughout their research and development work. The category includes all of the following items: oligonucleotides, enzymatic reagents which consist of polymerases and ligases and restriction enzymes, cloning kits, chassis organisms which include bacterial yeast and mammalian cell lines, and software platforms which scientists use for biological design and modeling. The products find regular application throughout synthetic biology workflows which span from initial development phases to production stages resulting in continuous use across various projects and applications.

Based on technology, the synthetic biology market is segmented into nucleotide synthesis & sequencing technologies, genetic engineering technologies, bioinformatics & computational biology, microfluidics & miniaturization, others. Nucleotide synthesis & sequencing technologies held the largest market share of 41.8% in 2025 and is expected to grow at a CAGR of 17.2% during 2026-2035.

• The synthetic biology industry has its most established and widely used technology segment through nucleotide synthesis and sequencing technologies. The technologies enable accurate DNA construction and validation and optimization processes which underpin essential workflows for research and development and commercialization. The broad range of applications in therapeutics and industrial biotechnology and agriculture and diagnostics makes these technologies essential for synthetic biology operations while they establish constant demand through their integration into biological engineering pipelines.
• The design process benefits from genetic engineering tools and bioinformatics and computational biology and microfluidics and miniaturization technologies which provide better design efficiency and experimental throughput and predictive capabilities. The technologies create a new application environment which establishes ''nucleotide synthesis and sequencing platforms'' as the primary ''platform'' for subsequent technology deployment. The synthetic biology value chain maintains its technological trajectory through nucleotide synthesis and sequencing technologies which serve as educational foundations for the entire industry.

Based on application, the market is segmented into pharmaceuticals and diagnostics, industrial chemicals & materials, agriculture & food production, energy & biofuels, others. Pharmaceuticals and diagnostics segment dominated the market with an approximate market share of 78.8% in 2025 and is expected to grow with the CAGR of 17.2% by 2035.

• The synthetic biology market functions through its most established application segment which includes pharmaceutical and diagnostic products. Scientists apply engineered genes and cells and biological systems for their research work which includes drug discovery and vaccine development and cell and gene therapies and molecular diagnostics development. Synthetic biology enables the development of precision medicine through its ability to create highly specific and reproducible and customized medical solutions which result in faster creation of new treatment and diagnostic systems. The segment remains vital to market operations because strong regulatory requirements and ongoing technological advancements work together to establish its importance.
• The market achieves sustainable growth through its diverse applications which include industrial chemicals and materials and agricultural and food production and energy and biofuels. The segments which use synthetic biology drive process innovation and cost optimization through their efforts to achieve better sustainability and efficiency and higher yield results. The industry needs to complete its industrial scale-up and commercial operations before it can start using these technologies. The pharmaceutical and diagnostic industries serve as the primary growth engines which maintain both market demand and technological progress.

The North America synthetic biology industry is growing rapidly on the global level with a market share of 39.6% in 2025.

• North America represents a mature and strategically important region in the global synthetic biology landscape. The region benefits from strong research infrastructure, early technology adoption, and a well‑established ecosystem spanning academia, startups, and large multinational corporations.

U.S. dominates the North America synthetic biology market, showcasing strong growth potential.

• The U.S. dominates the North American synthetic biology indusrtry, driven by robust investment in life sciences, widespread adoption of advanced genome engineering tools, and a strong focus on translational research. The country establishes itself as a market-driving force through its government support programs and developed venture capital systems and its industrial sector and research institutions working together through formal partnerships.

Europe synthetic biology market growing in the industry with revenue of USD 7.8 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The European synthetic biology indusrtry is characterized by its strong emphasis on sustainability, regulatory compliance, and collaborative research. The region uses synthetic biology to develop healthcare agricultural and industrial manufacturing solutions which achieve its environmental and efficiency targets. The public sector promotes bio-based innovation through its active policy support which helps the market to establish engineered biological systems.

The Asia Pacific synthetic biology market is anticipated to grow at a CAGR of 17% during the analysis timeframe.

• Asia Pacific is emerging as the most dynamic growth region in the synthetic biology indusrtry. The market growth emerges from three main forces which include industrialization and biotechnology development and increasing investments in sustainable manufacturing and healthcare. Research funding and infrastructure development and regulatory reform work together to build domestic research capacity in all countries of the region.

Latin America synthetic biology accounted for 2.2% market share in 2025 and is anticipated to show highest growth over the forecast period.

• Latin America represents a developing but increasingly attractive market for synthetic biology. The market expands through agricultural biotechnology growth and sustainable production development and research capability enhancement.

Middle East & Africa Synthetic Biology accounted for 1.3% market share in 2025 and is anticipated to show lucrative growth over the forecast period.

• The synthetic biology indusrtryin the Middle East and Africa is at an early but evolving stage, supported by national diversification strategies and investments in biotechnology and life sciences. The growing demand for enhanced healthcare services and better resource management results in a positive atmosphere for adopting synthetic biology solutions.

Synthetic Biology Market Share

The top 5 companies in synthetic biology industry include BASF, GenScript, ATUM, Twist Bioscience, Integrated DNA Technologies. These are prominent companies operating in their respective regions covering approximately 25% of the market share in 2025. These companies hold strong positions due to their extensive experience in Synthetic Biology indusrtry. Their diverse product portfolios, backed by robust production capabilities and distribution networks, enable them to meet the rising demand across various regions.

• BASF utilized industrial biotechnology and synthetic biology in the blue world of chemical processes and bio-based manufacture involving engineered microbes and fermentation platforms. Digital tools integrated with biotechnologies will accelerate both bioprocess development in protein engineering and enzyme discovery. Biopolymers, flavors, enzymes, and sustainable feedstocks for consumer and industrial products are some application areas. BASF partners with biotechnology firms to further enhance flexibility in raw material and bio-manufacturing capability.
• GenScript's activities cover Life Science Services, Industrial Synthetic Biology Products, and Cell Therapy Platforms, encompassing gene synthesis and protein engineering along with certain CRISPR tools. Its activities assist synthetic biology workflow by an array of technologies: DNA assembly, molecular engineering, and construction of microbial strains. It has a worldwide presence with facilities in the U.S., China, Singapore, Japan, and Europe sitting on its mission to assist researchers, the pharmaceutical industry, and the industrial biotech sector. GenScript's offerings support the design-up-build-test cycle for applications from therapeutics to industrial enzyme manufacture.
• ATUM offers synthetic DNA, gene design, protein engineering, and cell-line development services built on their proprietary platforms GeneGPS and VectorGPS. Synthetic biology at the company is supported by transposon-based gene delivery tools with machine learning design and codon optimization algorithms. It provides service to its clients in biotechnology, pharmaceuticals, chemicals, and academia with a focus on theoretical expression optimization and engineered-protein development. R&D services are customized in California for ATUM with respect to custom constructs.
• Integrated DNA Technologies enables very high-throughput design-build-test cycles in synthetic biology by supplying gene fragments, oligos, vectors, and custom constructs. In synthetic biology, its custom solutions program offers a tailor-made service for complex genes and applications requiring non-standard constructs and/or diverse multi-site cloning. IDT has developed a synthetic biology facility flexible to work with sponsors with diverse manufacturing workflows. These capabilities can be used across the industry for research and healthcare with regard to engineered DNA systems.
• Twist Bioscience manufactures high-throughput synthetic DNA leveraging its semiconductor-based platform that miniaturizes DNA-writing chemistry. It includes genes, oligo pools, variant libraries, and useful tools that support synthetic biology research, screening, and engineering. The company is focusing its synthetic DNA applications on therapeutics, agriculture, industrial chemistry, and NGS workflows. Twist is also actively engaging in partnerships and licensing technologies to expand access to long DNA and engineered-library capabilities

Synthetic Biology Market Companies

Major players operating in the synthetic biology industry include:

• Novozymes

• BASF
• GenScript
• ATUM
• Integrated DNA Technologies
• Twist Bioscience
• Biomax Informatics
• Pareto Biotechnologies
• Blue Heron
• TeselaGenSyntrox
• Thermo Fisher Scientific
• Gevo Inc
• Royal DSM
• Bristol-Myers Squibb
• Amyris

Synthetic Biology Industry News

• In May 2025, Mirosynth DNA molecules, a breakthrough in facilitating the building of complex synthetic DNA sequences, are released by Ribbon Bio. This further development will speed up the application in the synthetic biology market by supplying researchers with more precise and versatile genetic tools. The new technology promises to open areas within healthcare, agriculture, and biomanufacturing.
• In October 2025, Ansa Biotechnologies, the trusted partner for DNA synthesis, announces the worldwide launch of its 50 kilobase (kb) Clonal DNA product, the longest sequence-perfect synthetic DNA available commercially. The new product on offer allows scientists to design and obtain complete, error-free DNA constructs in 25 days or fewer, thus avoiding compromises that have beset gene synthesis for decades.

These synthetic biology market research report includes in-depth coverage of the industry, with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, by Product Type

• Core Products
  • Synthetic Nucleic Acids
  • Genetic Parts & Vectors
  • Others
• Enabling Products
  • Gene Synthesis & Sequencing Platforms
  • Genetic Engineering Kits & Reagents
  • Others
• Enabled Products
  • Therapeutic Biologics & Cell Therapies
  • Bio-Based Chemicals & Materials
  • Others

Market, by Technology

• Nucleotide Synthesis & Sequencing Technologies
• Genetic Engineering Technologies
• Bioinformatics & Computational Biology
• Microfluidics & Miniaturization
• Others

Market, by Application

• Pharmaceuticals and diagnostics
• Industrial Chemicals & Materials
• Agriculture & Food Production
• Energy & Biofuels
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa